Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Düsing, R.
Right arrow Articles by Mengden, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Düsing, R.
Right arrow Articles by Mengden, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 1317-1321
© 2001 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Compliance with drug therapy—new answers to an old question

Rainer Düsing, Katja Lottermoser and Thomas Mengden

Medizinische Universitäts-Poliklinik, Bonn, Germany

Keywords: drug therapy; compliance

Introduction

Compliance with medical recommendations, especially with drug therapy, has been recognized to represent a complex challenge since its first mentioning by Hippocrates about 2400 years ago [1]. An in-depth scientific approach towards this problem, however, can only be traced over the past three decades with a strong increase in published studies over this period of time (Figure 1Go). As is generally true in medicine and other scientific subjects, the availability of reliable methods is of crucial importance for scientific progress. Thus, the development of electronic medication event monitoring systems (MEMS) in 1977 has provided the basis for a rapid expansion in understanding the compliance issue [2]. To date, this method represents the ‘gold standard’ for measuring compliance and its application in many areas of drug research and in clinical practice is rapidly expanding [3,4]. In the following, we will briefly review . . . [Full Text of this Article]

Definitions and methods

Electronic medication event monitoring

Non-compliance or ‘how much compliance is enough’

Variable compliance: causes and consequences

Typical patterns of non-compliance

Strategies to cope with variable compliance

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Therapeutic Advances in GastroenterologyHome page
J. P. A. O'Connor, I. Taneike, and C. O'Morain
Review: Improving compliance with Helicobacter pylori eradication therapy: when and how?
Therapeutic Advances in Gastroenterology, September 1, 2009; 2(5): 273 - 279.
[Abstract] [PDF]

Home page
 Ann Rheum DisHome page
N. Costedoat-Chalumeau, Z. Amoura, J.-S. Hulot, G. Aymard, G. Leroux, D. Marra, P. Lechat, and J.-C. Piette
Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus
Ann Rheum Dis, June 1, 2007; 66(6): 821 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
P. A. Tabor and D. A. Lopez
Comply With Us: Improving Medication Adherence
Journal of Pharmacy Practice, June 1, 2004; 17(3): 167 - 181.
[Abstract] [PDF]